Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin

Japanese Journal of Cancer Research

Volumn 92, Issue 11, 2001, Pages 1242-1250

  Komuro, Yuuki ^a,c   Udagawa, Yasuhiro ^b   Susumu, Nobuyuki ^a   Aoki, Daisuke ^a   Kubota, Tetsuro ^a   Nozawa, Shiro ^a  

^a KEIO UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAITAMA NATIONAL HOSPITAL   (Japan)

Author keywords

Cisplatin; Multidrug resistance associated protein; Paclitaxel; Resistance; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CISPLATIN; IRINOTECAN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; OUABAIN; PACLITAXEL; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CELL LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CELL DIVISION; CISPLATIN; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OUABAIN; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0035213654     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2001.tb02146.x     Document Type: Article

References (35)

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer
2. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells
3. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
4. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer
5. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP)
6. Establishment and characterization of a human chorionic gonadotropin (hCG) producing cell line (RTSG) from an ovarian epithelial cancer
7. Establishment of a cisplatin-resistant human ovarian cancer cell line
8. Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs
9. Terminology in the description of drug-radiation interactions
10. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A Rational approach to clinical protocol design
11. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
12. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry
13. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction
14. Possible mechanisms of resistance to cis-diamminedichloroplatinum (II) of human ovarian cancer cells
15. Characterization of resistance mechanism to cis-diamminedichloroplatinum (II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro
16. +-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum (II) in human ovarian carcinoma cells
17. Anti-cancer-prostaglandin-induced cell-cycle arrest and its modulation by an inhibitor of the ATP-dependent glutathione S-conjugate export pump (GS-X pump)
18. Gamma-glutamyl-cysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance
19. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP
20. Expression of multidrug resistance protein-related genes in lung cancer: Correlation with drug response
21. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump
22. Coordinated induction of MRP/GS-X pump and γ-glutamylcysteine synthetase by heavy metals in human leukemia cells
23. 4 small transporter in cisplatin-resistant human KB cells
24. +-dependent and -independent transport of uridine and its phosphorylation in mouse spleen cells
25. Frequent coordinated overexpression of the MRP/GS-X pump and γ-glutamylcysteine synthetase genes in human colorectal cancers
26. Transport of amphipathic anions by human multidrug resistance protein 3
27. Increased expression of an ATP-binding cassette super-family transporter, multidrug resistance protein 2, in human colorectal carcinomas
28. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents
29. Analysis of expression of cMOAT(MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines
30. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules
31. Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines
32. Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells
33. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines
34. Modulation of DNA topoisomerase I activity by p53
35. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53